Mutations on the G12/G13 positions in Ras proteins, including HRAS, KRAS, and NRAS, showed increased sensitivity to MEK inhibitors AZD6244 and PD-0325901 in multiple cancer types (BLCA, CESC, HNSC, PAAD, THYM, UCEC, and UCS) (Fig. 7D). This evidence concerns the gene HRAS and bladder transitional cell carcinoma.